Search Results 651-660 of 16434 for infliximab

  1. Study of Dexamethasone Plus IXAZOMIB or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis - Mayo Clinic

    Treatment options will include: dexamethasone alone, dexamethasone plus an alkylating agent (melphalan or cyclophosphamide), or dexamethasone plus an ...

  2. A Study to Evaluate Firstline Pembrolizumab Alone or in Combination with Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients with Stage IV Non-squamous Non-small Cell Lung Cancer - Mayo Clinic

    Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by ...

  3. Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia - Mayo Clinic

    Onvansertib is a drug that binds to and inhibits an enzyme called PLK1, preventing cancer cell proliferation and causing cell death. Participation eligibility.

  4. https://www.mayoclinic.org/arabic_organization_concepts.xml

  5. Efficacy And Safety Of Nintedanib In Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - Mayo Clinic

    There is currently no efficacious treatment available for PF-ILD. Based on its efficacy and safety in Idiopatic Pulmonary Fibrosis (IPF), it is anticipated that ...

  6. A Study of Cemiplimab in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy - Mayo Clinic

    The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced ...

  7. Study of Canakinumab in Patients With Myelofibrosis - Mayo Clinic

    The purpose of this study is to estimate the effectiveness of Canakinumab treatment in patients with primary myelofibrosis (PMF), post PV-MF (Post-Polycythemia ...

  8. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL - Mayo Clinic

    The goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two antibodies, veltuzumab and epratuzumab. For treatment, epratuzumab ...

  9. Oncology (Medical) - Clinical trials

    The purpose of this study is to identify the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian ...

  10. Digestive Diseases Clinical Trials - Medical Professionals

    There is evidence that colonic inflammation plays a major role in colon polyp and colorectal cancer development. For example, inflammatory bowel disease is a ...